Sawtooth Solutions, LLC Seagen Inc. Transaction History

Sawtooth Solutions, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	SELL	$191.51 - $216.16 $311,395 - $351,476	-1,626 Reduced 18.44%	7,191 $1.53 Million
Q2 2023 Jul 26, 2023	BUY	$187.64 - $206.25 $227,044 - $249,562	1,210 Added 15.91%	8,817 $1.7 Million
Q1 2023 Apr 27, 2023	BUY	$127.59 - $203.08 $219,709 - $349,703	1,722 Added 29.26%	7,607 $1.54 Million
Q4 2022 Feb 02, 2023	SELL	$117.37 - $139.17 $81,337 - $96,444	-693 Reduced 10.54%	5,885 $756,000
Q3 2022 Oct 12, 2022	BUY	$135.27 - $180.11 $103,346 - $137,604	764 Added 13.14%	6,578 $900,000
Q2 2022 Jul 19, 2022	BUY	$108.81 - $179.33 $126,654 - $208,740	1,164 Added 25.03%	5,814 $1.03 Million
Q1 2022 May 20, 2022	SELL	$119.61 - $157.85 $586,567 - $774,096	-4,904 Reduced 51.33%	4,650 $670,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $799,817 - $1.07 Million	5,610 Added 142.24%	9,554 $1.48 Million
Q3 2021 Nov 09, 2021	SELL	$142.45 - $169.82 $20,655 - $24,623	-145 Reduced 3.55%	3,944 $670,000
Q2 2021 Sep 01, 2021	BUY	$135.08 - $161.1 $96,447 - $115,025	714 Added 21.16%	4,089 $646,000
Q1 2021 May 13, 2021	BUY	$137.51 - $190.8 $464,096 - $643,950	3,375 New	3,375 $469,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Sawtooth Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Sawtooth Solutions, LLC with notifications on news.